Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CU01-1001
- Development stage
- Phase 2
- Lead developer
- Curacle
- Modality
- Small Molecules
01
Overview
CU01-1001 is a small molecule drug developed by Curacle Co., Ltd. for the treatment of diabetic nephropathy. It acts as an NRF2 stimulant and targets both NRF2 and TGF-β pathways. The drug is currently in Phase II clinical trials for diabetic nephropathy with albuminuria.
- Other names
- CU-01CU01CU 01CU01-1001CU-01-1001CU 01-1001
02
Targets
NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)
Beyond the preview
Go deeper on CU01-1001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CU01-1001.